[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"New Mexico Cancer Research Alliance\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":112},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,40,69,92],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":5},"100626527","phase-2-progestins-for-the-treatment-of-endometrial-cancer-or-precancers-of-the-uterus-before-surgery-the-pro-window-trial-100626527",false,"NCT07436793","Progestins for the Treatment of Endometrial Cancer or Precancers of the Uterus Before Surgery, The Pro-Window Trial","Evaluating Promising Progestins in Endometrial Cancer Through a Rotating Umbrella Surgical Window Trial - The PRO-WINDOW TRIAL for Endometrial Cancer","Inclusion Criteria:\n\n* Patients must have a histologically proven diagnosis of endometrioid endometrial adenocarcinoma by endometrial curettage or biopsy within 8 weeks prior to registration. Pathology reports should document adequate tissue from the biopsy and slides should be reasonable determined to be obtainable by the study team for study use\n* History\u002Fphysical examination within 42 +\u002F- 5 days of planned surgical procedure (18-21 days from day 1)\n* Age ≥ 18\n* The trial is open only to women with primary endometrioid adenocarcinoma of the uterine corpus (all histologic grades and stages) who are planned and appropriate for primary surgical treatment to include removal of the uterine corpus via any surgical modality. The patient must be considered a suitable surgical candidate\n* Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, 2, or 3 within 28 days prior to registration\n* Formalin-fixed, paraffin-embedded tumor tissue from the biopsy or curettage must be reasonably deemed available for submission along with the corresponding pathology report\n* Platelets ≥ 100,000\u002Fμl\n* Granulocytes (absolute neutrophil count \\[ANC\\]) ≥ 1,500\u002Fμl\n* Creatinine ≤ 1.6 mg\u002Fdl\n* Serum glutamic-pyruvic transaminase (SGPT) (alanine transaminase \\[ALT\\]) ≤ 3 x upper limits of normal\n* Bilirubin within institutional normal limits\n* The patient must provide study-specific informed consent and authorization permitting release of personal health information prior to study entry\n* Any patients of childbearing potential must have a negative pregnancy test\n\nExclusion Criteria:\n\n* Patients with any non-endometrioid histology (such as serous, clear cell, or carcinosarcoma or mixed)\n* Patients who have received prior progestin or anti-estrogen therapy during the 3 months before the diagnosis of endometrioid adenocarcinoma of the uterine corpus is established. Estrogen therapy alone is allowed\n* Patients with ECOG performance status of 4\n* Patients with history of deep venous thrombosis or pulmonary embolism within the past 2 years or ongoing thromboembolic disorders\n* Patients who have previously received systemic, radiation or other treatment for uterine cancer\n* Patients for whom formalin-fixed, paraffin-embedded tumor tissue from the biopsy or curettage is scant or unavailable\n* Patients with a suspected or known peanut allergy\n* Patients with serious comorbidities or gastrointestinal obstruction that precludes taking oral medications or have malabsorptive disease","FEMALE","18 Years",{"count":19,"type":20},140,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","This phase II trial tests compares the effect of progestins, megestrol acetate to micronized progesterone, in treating patients with endometrial cancer and precancers of the uterus (atypical endometrial hyperplasia) before surgery. Progestins, similar to the natural hormone progesterone, are approved drugs used in birth control and hormone replacement pills, and some can treat uterine endometrial cancers. In the initial comparison of this rotating umbrella trial, megestrol acetate, a progestin, will be compared to micronized progesterone, a form of natural progesterone that is a hormone produced by body normally. Hormone therapy using megestrol acetate and micronized progesterone may be effective in treating patients with endometrial cancer or atypical endometrial hyperplasia before surgery, and understanding the tissue effects of each agent on the malignant endometrium will uncover novel mechanistic and biomarker data to understand how best to advanced hormone therapy for endometrial cancer.",[26,27],"Endometrial Endometrioid Adenocarcinoma","Endometrial Hyperplasia","RECRUITING","2026-06-30",{"date":31,"type":32},"2026-07-02","ACTUAL",{"date":34,"type":32},"2026-06-15",{"date":36,"type":20},"2031-06-30",{"name":38,"class":39},"New Mexico Cancer Research Alliance","OTHER",{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":46,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":48,"minAge":17,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":21,"phases":51,"briefSummary":53,"conditions":54,"keywords":56,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":68},"100532058","engagement-of-american-indians-of-southwestern-tribal-nations-in-cancer-genome-sequencing-100532058","NCT06207864","Engagement of American Indians of Southwestern Tribal Nations in Cancer Genome Sequencing","Participant Engagement - Cancer Genome Sequencing (PE-CGS) Research Center: Engagement of American Indians of Southwestern Tribal Nations in Cancer Genome Sequencing","PE-CGS","Inclusion Criteria:\n\n* The PE-CGS Research Center is only recruiting and sequencing tumors for adult-onset cancers (patients and survivors) among the American Indian Tribes, Nations, and Pueblos of New Mexico and adjacent states\n* Male or female adults (18 years) or older\n* Cancer patient undergoing active treatment or a cancer survivor\n* Self-identify as American Indian\n\nExclusion Criteria:\n\n* Cognitively impaired\n* Adults unable to consent for themselves\n* Individuals who are not yet adults\n* Prisoners","ALL",{"count":50,"type":20},1001,[52],"NA","This clinical trial studies engagement strategies for recruiting American Indians (AI) of Southwestern Tribal Nations for cancer genome sequencing. American Indians in the Southwest have higher rates of some types of cancer, such as cancers that arise in the liver, kidney, breast, and colon. American Indians with cancer may also live for less time than people from other population groups who have been treated for the same cancer. Damage to the cells of the body, acquired as people live, grow older, and are exposed to the environment, causes genetic changes in cells that can lead to cancer. This study may help researchers learn how these genetic changes in cells cause cancer and understand how and why cancer is arising in American Indians in the Southwest. This may help better prevent and treat cancer in the future.",[55],"Malignant Neoplasm",[46,57,58,59],"Southwestern Tribal Nations","Cancer Genome Sequencing","American Indians","2025-11-11",{"date":62,"type":32},"2025-11-13",{"date":64,"type":32},"2022-03-22",{"date":66,"type":20},"2030-12-31",{"name":38,"class":39},1,{"id":70,"slug":71,"hasResults":11,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":75,"eligibilityCriteria":76,"healthyVolunteers":11,"sex":48,"minAge":17,"maxAge":4,"enrollmentInfo":77,"targetDuration":4,"studyType":79,"phases":4,"briefSummary":80,"conditions":81,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":68},"100360766","total-cancer-care-protocol-a-lifetime-partnership-with-patients-who-have-or-may-be-at-risk-of-having-cancer-100360766","NCT03977402","Total Cancer Care Protocol: A Lifetime Partnership With Patients Who Have or May be at Risk of Having Cancer","INST UNM 1521: Total Cancer Care Protocol: A Lifetime Partnership With Patients Who Have or May be at Risk of Having Cancer","TCCP","Inclusion Criteria:\n\n* 18 years of age and older.\n* Has a diagnosis of cancer or is suspected of having cancer.\n* Able to understand and sign the Informed Consent form directly.\n* Pregnant women are permitted to be enrolled.\n\nExclusion Criteria:\n\n* Prisoners",{"count":78,"type":20},47500,"OBSERVATIONAL","The overall objective of this study is to ultimately develop an improved standard of cancer care by facilitating new cancer research, clinical trials, new technology, new informatics solutions, and \"personalized medicine\" for the University of New Mexico Comprehensive Cancer Center (UNMCCC) and the Oncology Research Information Exchange Network (ORIEN) Consortium of academic medical centers, community hospital systems, and other health care providers. To bring new translational research to the community, the ORIEN consortium has initiated the ORIEN Total Cancer Care Program (TCCP). The TCCP establishes a unique collection of blood, tissue, other biological samples and their associated data (survey data, medical records data, cancer registry data, and other related data) from thousands of patients with cancer or at risk of having cancer. This is not a treatment trial. It is a study designed to create a centralized data and tissue repository.",[82,83],"Cancer","Cancer Risk","2025-05-20",{"date":86,"type":32},"2025-05-22",{"date":88,"type":32},"2016-01-27",{"date":90,"type":20},"2037-12-31",{"name":38,"class":39},{"id":93,"slug":94,"hasResults":11,"nctId":95,"briefTitle":96,"officialTitle":97,"acronym":4,"eligibilityCriteria":98,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":99,"targetDuration":4,"studyType":79,"phases":4,"briefSummary":101,"conditions":102,"keywords":104,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":106,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":111,"locationsCount":68},"100358150","laboratory-study-of-cancer--immune-cells-in-ascites-fluid-of-ovarian-cancer-patients-to-test-alternative-therapies-100358150","NCT03943316","Laboratory Study of Cancer & Immune Cells in Ascites Fluid of Ovarian Cancer Patients to Test Alternative Therapies","Single Institution (UNM) Prospective Laboratory Study of Cancer and Immune Cells in the Ascites Fluid of Ovarian Cancer Patients to Test Alternative Therapies","Inclusion Criteria:\n\n* All female participants, regardless of ethnicity, who are undergoing cytoreductive surgery for ovarian cancer are eligible for this study\n* All participants will be eighteen years old or older\n* Patients must be suspected of having a pathological diagnosis or clinical suspicion of ovarian cancer and be scheduled for surgery for tumor resection.\n* Ability to understand and the willingness to sign a written informed consent document.\n* Pathologic confirmation of a diagnosis of epithelial adenocarcinoma of the ovary, fallopian tube, or primary peritoneal cancer (serous, mucinous, clear cell, endometrioid, undifferentiated, mixed, transitional cell)\n* Women of childbearing potential must have a negative qualitative serum pregnancy test ≤ 2 weeks prior to study entry.\n* A female of child-bearing potential is any woman (regardless of sexual orientation, having undergone a tubal ligation, or remaining celibate by choice) who meets the following criteria:\n\n  * Has not undergone a hysterectomy or bilateral oophorectomy; or\n  * Has not been naturally postmenopausal for at least 12 consecutive months (i.e., has had menses at any time in the preceding 12 consecutive months).\n\nExclusion Criteria:\n\n* We do not intend to include participants if they are unable to provide informed consent for this study themselves (e.g. mentally ill patients who require health care proxies to consent for any medical intervention), or vulnerable populations such as prisoners.\n* Minors under age eighteen.\n* Pregnant women.\n* Final pathologic diagnosis that does not confirm invasive epithelial ovarian, tubal, or primary peritoneal cancer",{"count":100,"type":20},100,"Ascites samples from women undergoing surgery for ovarian cancer will be collected for use in translational research.",[103],"Ovarian Cancer",[103,105],"Ascites",{"date":86,"type":32},{"date":108,"type":32},"2015-12-02",{"date":110,"type":20},"2027-12-31",{"name":38,"class":39},""]